Editas Medicine, Inc.

Good morning and welcome to the Editas Medicine third quarter 2021 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised this call is being recorded at the company's request. I would now like to turn the call over to Ron Moldaver, Investor Relations at Editas Medicine.

Thank you, Melissa. Good morning, everyone, and welcome to our third quarter 2021 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available on the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A. As a reminder, various remarks that we make during this call about the company's future expectations plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our most recent annual report on Form 10-K, which is on file with the SEC and is updated by our subsequent filings. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. Now, I will turn the call over to our Chief Executive Officer, Jim Mullen.

Thanks, Ron, and good morning, everyone. I'm joined today by several members of the EDITAS executive team, including Mark Sherman, our Chief Scientific Officer, Lisa Michaels, our Chief Medical Officer, and Michelle Robertson, our Chief Financial Officer. I want to start off by providing some highlights from the third quarter, including some important milestones for EDITAS. In our first-ever clinical data readout, we announced positive initial data from our ongoing Phase I-II brilliance trial of EDIT-101 for the treatment of LCA10. including clinical evidence of gene editing and potential early clinical benefit. We are dosing patients in the adult high-dose cohort and enrolling patients in the first of two pediatric cohorts of that trial. The Ruby study of Edit 301 for sickle cell diseases is enrolling patients, and we expect to begin dosing in the first half of 2022. The pre-IND work for EDIT301 in transfusion-dependent beta thalassemia is progressing, and we remain on track to follow the IND before year-end. And in our cell therapy platform, Bristol-Martin Squibb opted into a fourth alpha-beta T-cell program this quarter, further advancing our successful collaborations. We presented data on our SLEEC technology platform demonstrating high-efficiency multi-transgene knock-in in multiple cell types, which we believe can enable improved CAR-T and CAR-NK cell therapies for solid tumors. At the upcoming CITSE and ASH conferences, we will present data showing improved tumor-killing ability through multiplex gene editing using SLEEC in our INK program. And finally, we've appointed Emma Reeve and Bernadette Connaughton to our Board of Directors. Both Emma and Bernadette are highly accomplished biopharma executives, and we look forward to their contributions to EDITAS. This quarter showcased a critical advancement for our clinical programs. The initial safety and efficacy data for the BRILLIANCE trial was an important milestone for patients with LCA10 and marked a key step in EDITAS' mission of providing life-changing gene-editing medicines to patients. These early data provide proof of concept for our in vivo gene editing platform and help strengthen our foundational technology with the clinical evidence to progress our broader pipeline. We made excellent progress this year with our programs and platform technologies, and we will continue an aggressive pace to deliver against our long-term objectives. With that, let me turn the call over to Lisa to review our clinical programs.